Protocols of IVF/ICSI in Poor Responders
Launched by CAIRO UNIVERSITY · Apr 18, 2020
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
The two groups of poor responders are randomized into either; a minimal dose stimulation protocol involving letrozole, recombinant FSH and GnRH antagonist versus a microflare conventional protocol with OCP, GnRH agonist and high dose recombinant FSH, in their IVF/ICSI cycles, primary outcome will be the number of oocytes retrieved.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- 1- More than 1 year of infertility 2 - Poor ovarian responder according to the Bologna criteria:
- • 1. Advanced maternal age
- • 2. Previous poor ovarian response
- • 3. Abnormal tests of ovarian reserve (AFC \< 5-7, AMH \<0.5-1.1 ng/ml)
- Exclusion Criteria:
- • 1. Age \> 43 years
- • 2. baseline FSH \>15 mIU/ml
- • 3. Previous ovarian surgery
- • 4. Ovarian endometrioma
- • 5. Uterine anomaly or myoma
- • 6. Any medical disorder
- • 7. Any hormonal disorder eg. hyperprolactinemia
- • 8. BMI \> 30 kg/m2
- • 9. Severe male factor
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Cairo, , Egypt
Patients applied
Trial Officials
Sarwat Ahwany, MD
Study Director
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials